vs
Side-by-side financial comparison of SAUL CENTERS, INC. (BFS) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
Xeris Biopharma Holdings, Inc. is the larger business by last-quarter revenue ($85.8M vs $75.1M, roughly 1.1× SAUL CENTERS, INC.). Xeris Biopharma Holdings, Inc. runs the higher net margin — 12.9% vs 8.7%, a 4.3% gap on every dollar of revenue. On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs 10.6%). Over the past eight quarters, Xeris Biopharma Holdings, Inc.'s revenue compounded faster (45.3% CAGR vs 6.2%).
Saul Centers, Inc. is a self-administered real estate investment trust (REIT) headquartered in the United States. It primarily owns, operates, and develops high-quality shopping centers, mixed-use properties, and multifamily residential assets, with its core portfolio concentrated in the Washington D.C. metropolitan area and other select high-growth U.S. regional markets.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
BFS vs XERS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $85.8M |
| Net Profit | $6.5M | $11.1M |
| Gross Margin | — | — |
| Operating Margin | 65.4% | 19.5% |
| Net Margin | 8.7% | 12.9% |
| Revenue YoY | 10.6% | 42.8% |
| Net Profit YoY | -19.6% | 316.7% |
| EPS (diluted) | $0.15 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $85.8M | ||
| Q3 25 | $72.0M | $74.4M | ||
| Q2 25 | $70.8M | $71.5M | ||
| Q1 25 | $71.9M | $60.1M | ||
| Q4 24 | $67.9M | $60.1M | ||
| Q3 24 | $67.3M | $54.3M | ||
| Q2 24 | $66.9M | $48.1M | ||
| Q1 24 | $66.7M | $40.6M |
| Q4 25 | $6.5M | $11.1M | ||
| Q3 25 | $10.5M | $621.0K | ||
| Q2 25 | $10.7M | $-1.9M | ||
| Q1 25 | $9.8M | $-9.2M | ||
| Q4 24 | $8.1M | $-5.1M | ||
| Q3 24 | $14.5M | $-15.7M | ||
| Q2 24 | $14.4M | $-15.0M | ||
| Q1 24 | $13.6M | $-19.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 73.6% | — | ||
| Q2 24 | 74.2% | — | ||
| Q1 24 | 72.8% | — |
| Q4 25 | 65.4% | 19.5% | ||
| Q3 25 | 69.1% | 9.0% | ||
| Q2 25 | 68.7% | 6.3% | ||
| Q1 25 | 66.5% | -5.1% | ||
| Q4 24 | 82.9% | 2.8% | ||
| Q3 24 | 72.8% | -23.8% | ||
| Q2 24 | 75.0% | -17.0% | ||
| Q1 24 | 72.4% | -35.1% |
| Q4 25 | 8.7% | 12.9% | ||
| Q3 25 | 14.6% | 0.8% | ||
| Q2 25 | 15.1% | -2.7% | ||
| Q1 25 | 13.6% | -15.3% | ||
| Q4 24 | 11.9% | -8.5% | ||
| Q3 24 | 21.5% | -29.0% | ||
| Q2 24 | 21.6% | -31.2% | ||
| Q1 24 | 20.4% | -46.7% |
| Q4 25 | $0.15 | $0.07 | ||
| Q3 25 | $0.32 | $0.00 | ||
| Q2 25 | $0.33 | $-0.01 | ||
| Q1 25 | $0.29 | $-0.06 | ||
| Q4 24 | $0.22 | $-0.02 | ||
| Q3 24 | $0.48 | $-0.11 | ||
| Q2 24 | $0.48 | $-0.10 | ||
| Q1 24 | $0.45 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.7M | $111.0M |
| Total DebtLower is stronger | $468.4M | $220.3M |
| Stockholders' EquityBook value | $307.8M | $13.7M |
| Total Assets | $2.2B | $383.5M |
| Debt / EquityLower = less leverage | 1.52× | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.7M | $111.0M | ||
| Q3 25 | $11.8M | $91.6M | ||
| Q2 25 | $5.3M | $59.3M | ||
| Q1 25 | $6.5M | $58.4M | ||
| Q4 24 | $10.3M | $71.6M | ||
| Q3 24 | $7.2M | $69.4M | ||
| Q2 24 | $6.9M | $77.6M | ||
| Q1 24 | $7.1M | $87.4M |
| Q4 25 | $468.4M | $220.3M | ||
| Q3 25 | $1.6B | $219.5M | ||
| Q2 25 | $1.6B | $218.6M | ||
| Q1 25 | $1.5B | $229.8M | ||
| Q4 24 | $455.8M | $232.1M | ||
| Q3 24 | $1.5B | $216.2M | ||
| Q2 24 | $1.4B | $230.5M | ||
| Q1 24 | $1.4B | $229.7M |
| Q4 25 | $307.8M | $13.7M | ||
| Q3 25 | $316.6M | $-861.0K | ||
| Q2 25 | $322.4M | $-19.3M | ||
| Q1 25 | $328.4M | $-35.1M | ||
| Q4 24 | $335.8M | $-29.6M | ||
| Q3 24 | $341.8M | $-28.3M | ||
| Q2 24 | $345.7M | $-19.3M | ||
| Q1 24 | $347.1M | $-9.2M |
| Q4 25 | $2.2B | $383.5M | ||
| Q3 25 | $2.2B | $370.2M | ||
| Q2 25 | $2.1B | $334.7M | ||
| Q1 25 | $2.1B | $315.5M | ||
| Q4 24 | $2.1B | $323.1M | ||
| Q3 24 | $2.1B | $321.1M | ||
| Q2 24 | $2.1B | $331.7M | ||
| Q1 24 | $2.0B | $336.6M |
| Q4 25 | 1.52× | 16.10× | ||
| Q3 25 | 5.02× | — | ||
| Q2 25 | 4.85× | — | ||
| Q1 25 | 4.70× | — | ||
| Q4 24 | 1.36× | — | ||
| Q3 24 | 4.37× | — | ||
| Q2 24 | 4.17× | — | ||
| Q1 24 | 4.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.8M | $20.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 15.35× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.8M | $20.0M | ||
| Q3 25 | $20.6M | $18.4M | ||
| Q2 25 | $26.6M | $182.0K | ||
| Q1 25 | $30.4M | $-10.0M | ||
| Q4 24 | $121.2M | $2.0M | ||
| Q3 24 | $26.5M | $-8.3M | ||
| Q2 24 | $32.1M | $-10.3M | ||
| Q1 24 | $33.8M | $-20.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-28.3M | — | ||
| Q2 24 | $-12.5M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -42.1% | — | ||
| Q2 24 | -18.7% | — | ||
| Q1 24 | -17.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 81.5% | — | ||
| Q2 24 | 66.7% | — | ||
| Q1 24 | 68.3% | — |
| Q4 25 | 15.35× | 1.81× | ||
| Q3 25 | 1.97× | 29.68× | ||
| Q2 25 | 2.48× | — | ||
| Q1 25 | 3.10× | — | ||
| Q4 24 | 14.98× | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | 2.22× | — | ||
| Q1 24 | 2.48× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFS
Segment breakdown not available.
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
